Table 4.
Serum levels of HDL parameters in various groups of AHF patients.
| HDL-apoA-II (mg/dL) |
HDL2-apoA-II (mg/dL) |
HDL3-apoA-II (mg/dL) |
||
|---|---|---|---|---|
| CAD | no (n = 158) | 23.3 (7.8–44.6) | 3.2 (1.3–6.4) | 4.5 (1.2–9.8) |
| yes (n = 156) | 25.2 (11.5–49.2) | 3.2 (1.5–7.7) | 5.2 (2.0–13.6) | |
| p = 0.005 | p = 0.625 | p = 0.002 | ||
| MetS | no (n = 98) | 25.9 (12.6–40.8) | 3.4 (1.8–6.4) | 5.1 (1.2–8.8) |
| yes (n = 216) | 23.6 (7.8–49.2) | 3.1 (1.3–7.7) | 4.8 (1.2–13.6) | |
| p < 0.001 | p = 0.054 | p = 0.450 | ||
| AF | no (n = (144) | 26.3 (11.5–49.2) | 3.3 (1.3–7.0) | 5.4 (1.2–11.8) |
| yes (n = 170) | 22.3 (7.8–44.0) | 3.0 (1.3–7.7) | 4.4 (1.2–13.6) | |
| p < 0.001 | p = 0.100 | p < 0.001 | ||
| Venous overload * |
no (n = 66) | 28.2 (17.2–49.2) | 3.4 (1.6–7.7) | 5.6 (2.9–13.6) |
| yes (n = 248) | 23.3 (7.8–40.8) | 3.1 (1.3–6.4) | 4.5 (1.2–9.5) | |
| p < 0.001 | p = 0.005 | p < 0.001 | ||
| AHF type | New onset AHF (n = 27) | 29.7 (16.2–44.6) | 3.5 (2.4–5.1) | 6.2 (2.9–9.8) |
| AHF following CHF (n = 287) | 23.7 (7.8–49.2) | 3.1 (1.3–7.7) | 4.7 (1.2–13.6) | |
| p < 0.001 | p = 0.016 | p < 0.001 |
Data are presented as median and minimum to maximum. Differences between the groups were tested with the Mann–Whitney U test. p-values < 0.017 are considered significant after a Bonferroni correction for multiple testing and are depicted in bold. AF, atrial fibrillation; AHF, acute heart failure; apoA-II, apolipoprotein A-II; CAD, coronary artery disease; CHF, chronic heart failure; HDL, high-density lipoprotein; HDL-p, HDL particle concentration; MetS, metabolic syndrome; S, small. * Any of the following: enlarged liver, peripheral edema, ascites, or jugular venous distension.